...Arena granted Ildong exclusive rights to develop and commercialize temanogrel in South Korea to treat thrombotic...
...stroke and peripheral artery disease. Ildong is responsible for conducting a Phase I trial with temanogrel...
...to use data generated by Ildong to develop and commercialize temanogrel outside of South Korea. Temanogrel...

...inhibition of serotonin-mediated amplification of platelet aggregation. Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Product: APD791...

...Phase Ia trial in 90 volunteers, APD791 was well tolerated without any dose-related adverse events. APD791...
...and at higher doses, the compound's half-life was 11 hours. Patients received oral doses of APD791...
...maximum tolerated dose has not been determined. Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Product: APD791...

...oral APD791 in 72 healthy adult volunteers. Arena Pharmaceuticals Inc. (ARNA), San Diego, Calif. Product: APD791...